Belinostat
Belinostat
Definition
A novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. Belinostat targets HDAC enzymes, thereby inhibiting tumor cell proliferation, inducing apoptosis, promoting cellular differentiation, and inhibiting angiogenesis. This agent may sensitize drug-resistant tumor cells to other antineoplastic agents, possibly through a mechanism involving the down-regulation of thymidylate synthase.
Also known as Beleodaq, BELINOSTAT, PXD 101, PXD-101, PXD101 — per NCIT
Also identified as
- ATC L01XH04 per RXNORM
- NCIT NCIT:C48812 per NCIT
- SCTID 704194004 per RXNORM
- SCTID 704195003 per RXNORM
- UNII F4H96P17NZ per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Mature T-cell and NK-cell non-Hodgkin lymphoma | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Lymphoid system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
1 entry above is marked DERIVED: Atlas Médico inferred it by combining two sourced claims, and no source asserts this link directly. Treat it as a navigation aid, not as a clinical statement.